DocGo (NASDAQ: DCGO) extends $26M stock repurchase program to June 30, 2026

Rhea-AI Filing Summary

DocGo Inc. extended the expiration date of its existing share repurchase program from December 31, 2025 to June 30, 2026. The program continues to authorize the company to repurchase up to $26 million of its common stock.

DocGo may buy shares from time to time through open-market purchases, privately negotiated transactions, or arrangements such as Rule 10b5-1 trading plans and accelerated share repurchase programs, during trading windows when it is not in possession of material non-public information. Repurchases may be funded with existing cash and cash equivalents, future cash flow, or proceeds of borrowings or debt offerings, and the program can be modified, suspended, or discontinued at any time.

Insights

Equity Capital Markets Analyst

DocGo extends time to use its existing $26M stock buyback.

DocGo's board approved an extension of its share repurchase program, moving the expiration from December 31, 2025 to June 30, 2026. The maximum authorization remains at $26 million of common stock, so this change affects timing rather than size.

The company may execute repurchases via open-market purchases, privately negotiated deals, or structures like Rule 10b5-1 trading plans and accelerated share repurchase programs, when in an open window and not holding material non-public information. Funding can come from existing cash, future cash flow, or borrowings, giving multiple potential sources of capital.

The program is discretionary and can be modified, suspended, or discontinued without notice, so actual impact depends on how many shares DocGo elects to repurchase before June 30, 2026. Future disclosures can show how much of the $26 million authorization is ultimately used.

0001822359FALSE00018223592025-12-122025-12-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): December 12, 2025

___________________________________

DOCGO INC.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware

001-39618

85-2515483

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

685 Third Avenue, 9th Floor, New York, New York

10017

(Address of principal executive offices)

(Zip Code)

(844) 443-6246

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common stock, par value $0.0001 per share

DCGO

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On December 12, 2025, the Board of Directors of DocGo Inc. (the “Company”) approved an extension of the expiration date of the Company’s current share repurchase program (“Repurchase Program”) from December 31, 2025 to June 30, 2026. As previously disclosed, pursuant to the Repurchase Program, the Company may purchase up to $26 million in shares of the Company’s common stock. Other than the extension of the program’s expiration date, no changes were made to the Repurchase Program.

Under the terms of the Repurchase Program, as extended, the Company may continue to purchase shares of its common stock on a discretionary basis from time to time through open market repurchases or privately negotiated transactions or through other means, including by entering into Rule 10b5-1 trading plans or accelerated share repurchase programs, in each case, during an “open window” and when the Company does not possess material non-public information.

The timing and actual number of shares repurchased under the Repurchase Program will depend on a variety of factors, including stock price, trading volume, market conditions, corporate and regulatory requirements and other general business considerations. The Repurchase Program may be modified, suspended or discontinued at any time without prior notice.

Repurchases under the Repurchase Program may be funded from the Company’s existing cash and cash equivalents, future cash flow or proceeds of borrowings or debt offerings.

The information in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DOCGO INC.
By:			/s/ Norman Rosenberg
Name:			Norman Rosenberg
Title:			Chief Financial Officer and Treasurer

Date: December 12, 2025

2

FAQ

What did DocGo (DCGO) announce regarding its share repurchase program?

DocGo's board approved an extension of its existing share repurchase program, moving the expiration date from December 31, 2025 to June 30, 2026, with all other terms unchanged.

How much stock can DocGo repurchase under the extended program?

The program authorizes DocGo to purchase up to $26 million in shares of its common stock, as previously disclosed.

What methods can DocGo use to repurchase DCGO shares?

DocGo may repurchase shares through open market transactions, privately negotiated deals, or other means, including Rule 10b5-1 trading plans and accelerated share repurchase programs, during open trading windows.

How will DocGo fund its share repurchases?

Repurchases under the program may be funded from DocGo's existing cash and cash equivalents, future cash flow, or proceeds of borrowings or debt offerings.

Is DocGo required to complete the full $26 million in repurchases?

No. The timing and actual number of shares repurchased will depend on factors such as stock price, trading volume, market conditions, and corporate and regulatory requirements, and the program can be modified, suspended, or discontinued at any time.

Is the information about DocGo’s repurchase program considered filed with the SEC?

The information about the repurchase program in this report is being furnished under Regulation FD and is not deemed "filed" for purposes of the Securities Exchange Act of 1934.